Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient.
Additional information:
This is a call off contract from framework 2023/S 000-028831 based on previous contracts usage.
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| Exact Sciences UK, Ltd. | 07484560 | £272,700 | LOBBYIST WPP Brands (UK) Limited (5 quarters) Burson Cohn & Wolfe (1 quarter) |
Government spending data: This supplier has received £1,720,620 in 84 payments (over £25k) from NHS England, Guy's and St Thomas' NHS FT, Manchester University NHS Foundation Trust, Worcestershire Acute Hospitals NHS Trust, East Sussex Healthcare NHS Trust and 2 more public bodies (2014-05-31 to 2026-02-02). View full payment history →